BreakBio’s patent-pending treatment is designed to make personalized vaccines that target several types of cancers, starting with metastatic colorectal cancer
Colorectal cancer is the second most deadly cancer, after lung cancer.
Existing treatments for this cancer are not effective.
Given that patients who have had poor results from chemotherapy, have no meaningful treatment options today, the FDA could award Breakthrough Therapy Designation. This is awarded if early clinical data shows “substantial improvement over existing therapy”. Achieving this breakthrough is our key goal.
BreakBio’s patent-pending Personalized Cancer Control (PCC)
Cancer Vaccine Tailor Made for Each patient.
Treatment is in two parts
BreakBio CANCER VACCINE
Proprietary AI Vaccine Design Model
Analyzes the cancer cells in each patient
Then BreakBio manufactures a unique vaccine per patient
Proven colorectal cancer (CRC) drugs
Reduces barriers to immune system and
Slows rate of growth of cancer cells
Two arms: One combination for patients who have not progressed on chemo
Different combination for patients who have progressed on chemo